Relay Therapeutics Inc. (RLAY)
NASDAQ: RLAYHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
RLAY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.93B
- EPS (TTM)
- -$1.56
- Dividend yield
- None
- 52-week range
- 5.83 – 21.27
- Day range
- 17.85 – 18.48
- Volume / Avg
- 3.43M / 2.81M
- Beta
- —
- Shares outstanding
- 219.14M
- Next earnings
- Nov 5, 2026
52-week range
RLAY stock today
Relay Therapeutics (RLAY) closed at $17.95 on Oct 7, down 4.22% (-$0.79), versus the S&P 500's 0.22% decline. At this level, RLAY sits in the middle of its 52-week range of $5.83 to $21.27: 15.6% below the high, set on Aug 19, 2026 and 207.9% above the low. RLAY is up 112.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 207.9%.
Relay Therapeutics has posted a net loss over the last twelve months (EPS of -$1.56), so its P/E ratio is not meaningful. Relay Therapeutics's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Relay Therapeutics
Company profileRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
- Headquarters
- Cambridge, MA
- Employees
- 202
- IPO year
- 2020
- Website
- relaytx.com
Financial highlights
Full financialsIn fiscal 2025, Relay Therapeutics generated $15.4 million in revenue, up 53.4% from fiscal 2024. Relay Therapeutics reported a net loss of $276.5 million, compared with a loss of $337.7 million a year earlier. Operating margin was -1971.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $15.36M | $10.01M | $25.55M | $1.38M | $3.03M |
| Growth | +53.44% | -60.83% | +1749.82% | -54.41% | -96.34% |
| Net income | $-276.48M | $-337.71M | $-341.97M | $-290.51M | $-363.87M |
| EPS (diluted) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$27.58+53.65%
- Strong buy 3
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.40
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-0.41 vs —
Relay Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs RLAY |
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs RLAY |
| CRSPCRISPR Therapeutics AG | 52.35 | -3.06% | $5.06B | vs RLAY |
| SRRKScholar Rock Holding Corporation | 42.20 | -0.59% | $5.14B | vs RLAY |
| DNLIDenali Therapeutics Inc. | 19.16 | -0.62% | $3.06B | vs RLAY |
| CGONCG Oncology Inc. | 62.38 | -1.98% | $5.53B | vs RLAY |
| BEAMBeam Therapeutics Inc. | 24.77 | -1.82% | $2.56B | vs RLAY |
| KODKodiak Sciences Inc | 91.08 | -1.36% | $5.72B | vs RLAY |
Indexes, lists and sector
Relay Therapeutics stock FAQ
What is Relay Therapeutics's stock price today?
RLAY last traded at $17.95 as of Oct 7, 4:00 PM EDT, down 4.22% on the day. Prices are delayed at least 15 minutes.
When is Relay Therapeutics's next earnings date?
Relay Therapeutics is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.40.
Who is Relay Therapeutics's CEO?
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS is the chief executive officer of Relay Therapeutics Inc., which has about 202 employees.
What is the RLAY 52-week high?
The 52-week high for RLAY is $21.27 and the 52-week low is $5.83. The stock is currently 15.6% below its high.